The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Mesenchymal stem cells therapy exerts neuroprotection in a progressive animal model of Parkinson’s disease
Open accessAbstract
Parkinson’s disease is a common progressive neurodegenerative disorder caused by the loss of dopaminergic neurons in the substantia nigra. We investigated whether cell therapy with human mesenchymal stem cells (hMSCs) had a protective effect on progressive dopaminergic neuronal loss in vitro and in vivo. In primary mesencephalic cultures, hMSCs treatment significantly decreased MG‐132‐induced dopaminergic neuronal loss with a significant reduction of caspase‐3 activity. In rats received systemic injection of MG‐132, hMSCs treatment in MG‐132‐treated rats dramatically reduced the decline in the number of tyrosine hydroxylase (TH)‐immunoreactive cells, showing an approximately 50% increase in the survival of TH‐immunoreactive cells in the substantia nigra compared with the MG‐132‐treated group. Additionally, hMSC treatment significantly decreased OX‐6 immunoreactivity and caspase‐3 activity. Histological analysis showed that the number of NuMA‐positive cells was 1.7% of total injected hMSCs and 35.7% of these cells were double‐stained with NuMA and TH. Adhesive‐removal test showed that hMSCs administration in MG‐132‐treated rats had a tendency to decrease in the mean removal time. This study demonstrates that hMSCs treatment had a protective effect on progressive loss of dopaminergic neurons induced by MG‐132 in vitro and in vivo. Complex mechanisms mediated by trophic effects of hMSCs and differentiation of hMSCs into functional TH‐immunoreactive neurons may work in the neuroprotective process.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
West, M. J., Slomianka, L., & Gundersen, H. J. G. (1991) · The Anatomical Record · doi:10.1002/ar.1092310411 · Cited by 2,994
Mesenchymal stem cells as trophic mediators
Caplan, A. I., & Dennis, J. E. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20886 · Cited by 2,992
Cited by
Stem Cell Paracrine Actions and Tissue Regeneration
Baraniak, P. R., & McDevitt, T. C. (2010) · Regenerative Medicine · doi:10.2217/rme.09.74 · Cited by 843
Johnson, T. V., Bull, N. D., Hunt, D. P., Marina, N., Tomarev, S. I., & Martin, K. R. (2010) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.09-4509 · Cited by 344
Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases
Uccelli, A., Laroni, A., & Freedman, M. S. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70121-1 · Cited by 306
Park, K.-S., Kim, Y.-S., Kim, J.-H., Choi, B., Kim, S.-H., Tan, A. H.-K., Lee, M.-S., Lee, M.-K., Kwon, C.-H., Joh, J.-W., et al. (2010) · Transplantation · doi:10.1097/tp.0b013e3181c7dc99 · Cited by 288
MSCs: Biological characteristics, clinical applications and their outstanding concerns
Si, Y.-L., Zhao, Y.-L., Hao, H.-J., Fu, X.-B., & Han, W.-D. (2011) · Ageing Research Reviews · doi:10.1016/j.arr.2010.08.005 · Cited by 259
Metadata
- Authors
- Park, H. J., Lee, P. H., Bang, O. Y., Lee, G., & Ahn, Y. H.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2008-09-16
- Volume
- 107
- Issue
- 1
- Pages
- 141-151
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W1985508547
- Cited by
- 185
- References
- 2
- FWCI
- 7.66
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mesenchymal stem cells therapy exerts neuroprotection in a progressive animal model of Parkinson’s disease. https://app.cochat.ai/papers/10.1111/j.1471-4159.2008.05589.x
- The paper
- Park, H. J., Lee, P. H., Bang, O. Y., Lee, G., & Ahn, Y. H. (2008). Mesenchymal stem cells therapy exerts neuroprotection in a progressive animal model of Parkinson’s disease. Journal of Neurochemistry. https://doi.org/10.1111/j.1471-4159.2008.05589.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.